'Defining moment' for Sydney viral vector facility

The TGA has granted Sydney's Viral Vector Manufacturing Facility (VVMF) a licence to manufacture therapeutic goods, marking a significant milestone for the company and sovereign capability for Australia.

The GMP licence enables VVMF to manufacture viral vectors under GMP conditions to support the development and commercialisation of advanced therapeutic products for Australian and global clients.

The licence authorises the GMP manufacture of replication-incompetent viral vectors using recombinant technology, as either sterile APIs or sterile Medicinal Products, together with associated Quality Control testing.

To see the whole article please log in.

Christine Spiteri

Log in with your member email for full access.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Email

Retype password

Not a member? Sign up here